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patients and those on immuno-suppression. There are four known
genotypes of HEV. The most recent candidate vaccines have been
two recombinant HEV vaccines. The ﬁrst of these vaccines was
based on a 56-kDa baculovirus-expressed ORF2 protein produced
in Spodoptera frugiperda cells, developed at the National Institutes
of Health, later licensed to GlaxoSmithKline. A phase II clinical
trial was conducted in 1,794 young male military recruits in Nepal
who received three doses 20g of the alum-adjuvanted vaccine
or placebo. Vaccinees were followed up to 2.2 years. The vaccine
showed a 95% efﬁcacy after the third dose. This vaccine study was
limited by the fact that it was tested on almost exclusively young
males, it did not measure the HEV infection rate and that antibody
titers declined by the end of the study. The second vaccine was
developed by researchers at Xiamen University in China, using a
new recombinant HEV protein expressed in Escherichia coli. This
vaccine, HEV 239 (Hecolin), was tested in a randomized, controlled
trial involving 112,604 healthy participants aged between 16-65
years in Jiangsu Province, where HEV genotypes 3 and 4 are more
prevalent. In those who received all three doses, 87% maintained
antibodies and remained protected against HEV for up to 4.5 years.
Its efﬁcacy against HEV genotypes 1 and 2, in pregnant women and
those younger than 16 years and older than 65 years are yet to
be assessed. The vaccine is licensed for use in China. Though not
yet prequaliﬁed by the WHO, the WHO is ready to assist national
health authorities and regulators in a rapid assessment of this vac-
cine. Today, the real challengewill be to get anHEVvaccine to those
who need it the most, at an affordable price.
http://dx.doi.org/10.1016/j.ijid.2016.02.137
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Background: Pentavalent combination vaccines perform a key
role in increasing vaccine coverage rate; and provide an efﬁcient
and reliable method of implementing WHO recommendations for
controlling diphtheria, tetanus, pertussis, hepatitis B andHib infec-
tions on a worldwide basis.
Methods & Materials: Study design: A phase III, multi-center,
randomized, single blinded study of a fully liquid pentavalent
DTwP-HepB-Hib investigational vaccine (Shan5TM) was conducted
across India in healthy toddlers and infants. Cohort 1 consisted of
15 toddlers aged 15-18months, administeredwith a single booster
dose; Cohort 2 consisted of 1085 infants aged 6-8 weeks, adminis-
tered 3 doses at 6-8, 10-12 and 14-16 weeks of age.
Objectives: Subjects in Cohort 1 were evaluated for safety and
immunogenicity. Immunogenicity and safety were evaluated in
Cohort 2 subjects vaccinated with a three-dose primary immu-
nization of either the investigational vaccine or a locally licensed
comparator vaccine (PentavacTM SD). Immune consistency anal-
ysis among three lots of the investigational vaccine, and immune
non-inferiorityanalysisofpooled (three lots)dataof investigational
vaccine versus comparator vaccine were also evaluated in cohort
2.
Results: The vaccines demonstrated comparable safety and
immune responses in cohort 1. In cohort 2, immune non-inferiority
against the comparator vaccine (primary endpoint) was demon-
strated for all ﬁve antigens and safety results (secondary endpoint)
were comparable between vaccine groups. Equivalent immune
consistency among three lots was observed for all antigens except
whole cell pertussis antigens, where a marginal variation was
observed. The variation was linked to the low power of the test
and concluded to be clinically insigniﬁcant.
Conclusion: The investigational, fully-liquid,whole-cell pertus-
sis (wP) containing pentavalent vaccine has a good safety proﬁle
and immunologically non-inferior to the licensed comparator vac-
cine. This study was the basis for licensure in India and also WHO-
prequaliﬁcation for international use.
http://dx.doi.org/10.1016/j.ijid.2016.02.138
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Background: Studies on county-level hot spots of sexually
transmitted infections (STIs) in the entire U.S. and their associ-
ation with socio-economic factors are lacking. In this study, we
used a combination of hot spot analysis (HSA) and spatial regres-
sion to examine the county-level correlates of the most commonly
reported curable sexually transmitted infections (STIs) in the U.S.
Methods & Materials: We obtained reported county-level total
case rates of chlamydia, gonorrhea, and primary and secondary
(P&S) syphilis in all counties in the 48 contiguous states using
the National Notiﬁable Disease Surveillance System (NNDDS).
We computed temporally-smoothed rates using 2008–2012 data.
Covariateswereobtained fromcounty-levelmultiyear (2008-2012)
American Community Surveys (ACS) from the US census. We con-
ducted HSA (applying the false discovery rate (FDR) correction) to
identify hot spot counties for all three STIs. Hot spots were deﬁned
as counties or clusters of countieswith rates above the globalmean
(p<0.05). We used logistic spatial regression with the spatial error
model (SEM) to determine the association between hot spots and
the covariates and variance inﬂation factor (VIF <10) analysis to
reduce the effect of multicollinearity on the coefﬁcients.
Results: HSA indicated that ≥ 80% of hot spots for each STI were
in the South. Spatial regression results indicated that, compared to
White non-Hispanics, a 1% increase in the percentage Black non-
Hispanic was associated with a 3.3% (p<0.01; chlamydia), 3.8%
(p<0.01; gonorrhea) and 2.5% (p<0.01; P&S syphilis) increase in
the odds of being a hot spot county (Table 1). Compared to the other
regions (West, Midwest andNortheast), counties in the Southwere
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Table 1
Spatial Regression Results
6.6 (p <0.01; chlamydia), 6.7 (p <0.01; gonorrhea) and 4.0 (p <0.01;
P&S syphilis) times more likely to be hot spots (Table 1).
Conclusion: Our study provides important information on hot
spot clusters of non-viral STIs in the entire US, including associa-
tions between hot spot counties and socio-economic/demographic
factors.
http://dx.doi.org/10.1016/j.ijid.2016.02.139
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Background: Vibrio cholerae accessory cholera enterotoxin
(ACE) is the third toxin alone with cholera toxin and zonula
occludens toxin that cause secretary diarrhea by activating Ca2+-
dependent Cl-/HCO3- symporters. However, the identity of the
underlying signalosomes and Cl- channel speciﬁcally activated by
ACE is unknown because of the low amount of toxin produced by
V. cholerae.
Methods&Materials: Using previously established biologically
active recombinant ACE, Ussing chamber and patch clamp tech-
niques, we examine the identity of unknown apical Cl- channel
activated by ACE to cause diarrhea.
Results: We observed ACE induce apical Cl conductance (ICl-)
sensitive to classical calcium activated Cl channel (CaCC) block-
ers such as NPPB, niﬂumic acid, and AO1 but was neither affected
by ANO1 (TMEM16A) speciﬁc inhibitor T16A-AO1 nor by CFTR
blocker, CFTRinh-172. In vivo mice ileal loop experiment reveal
similar sensitivity of ACE induced ﬂuid accumulation in presence
of various CaCC inhibitors. Based on these pharmacological studies,
we hypothesized ACE activated CaCC ANO6 (TMEM16F) to induce
apical Cl- secretion. This hypothesis validated by robust ANO6
expression in intestinal epithelial cell model Caco2 cell line and
reduced ICl in ANO6 knockdown Caco2 cell relative to wild type
Caco2 cells. The role of ANO6 in ACE induced Cl- secretion was
further conﬁrmed by measuring whole cell patch clamp record-
ings of Cl- currents upon ACE exposure in HEK293 cells transiently
expressing ANO6-GFP but not ANO1-mCherry. However, treat-
ment with calcium ionophore A23187 induced strong outwardly
rectifying ANO1 and ANO6 currents in these HEK 293 cells. Sur-
prisingly, ACE was not able to induce [Ca2+]i rise in these cells.
Together, these data indicate ACE elicits whole cell Cl- currents
by calcium-independent mechanism of ANO6 activation by ACE.
Further investigation reveal Caco2 cells expose to ACE cause signif-
icant RhoA translocation to plasmamembranewhile ACE evoke ICl-
decreases in presence of RhoA kinase (ROCK) inhibitor, H1152 and
PI4K inhibitor, wortmannin and PAO which reduces plasma mem-
brane PIP2 level. We have also identify PIP2 binding motif at the
N-terminal sequence among human and mouse ANO6 variants.
Conclusion: We conclude increased plasma membrane PIP2
level via RhoA-ROCK-PIP2 signaling cascade induced speciﬁc acti-
vation of ANO6 by during ACE mediated secretary diarrhea.
http://dx.doi.org/10.1016/j.ijid.2016.02.140
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Background: Antimicrobial Management Teams (AMT) play
an integral role in modifying antimicrobial utilization (AU). In
2004, AMT at Shands UF developed restricted antimicrobial
policy (RAP) with institutional criteria for carbapenems (CAR),
piperacillin/tazobactam (P/T), daptomycin (DAP), echinocandins
(EC), cefepime (CEF) and ﬂuoroquinolones (FQ). In 2008, AMT was
disassembled due to pharmacist attrition but RAP remained under
Infectious Diseases (ID). AMTwas re-initiated in 2010 and later fur-
ther expanded.We report the experience of the AMTover a 10-year
period and the impact on consumption, resistance, drug costs and
various oppurtunities, challenges and strategies.
Methods & Materials: A retrospective evaluation was per-
formed to compare the consumption of targeted antimicrobials,
measured as deﬁned daily dose per 1000 patient days, before and
after AUmanagement strategieswere initiated and alsowhen AMT
was disassembled and again when it was re-initiated. AU, Acquisi-
tion costs (AC) and Resistance rates (RR) from2003were compared
to 2006/7 and also from 2008 was compared to 2010. Following re-
implementation, AMT’s central role focusedonRAPadherencewith
direct prescriber feedback on Days 3 and 7 of therapy.
Results: With Initiation of AMT in 2004, consumption of most
anti-pseudomonal antibiotics fell: IMI (-80%), P/T (-22%), T/C (-60%),
CEF (-3.8%) and FQs (-37%). Resistance among Pseudmonas to tar-
geted antibiotics has stabilized and displays a downward trend.
Antimicrobial drug acquisition costs decreased by 18%.
Following loss of AMT, antimicrobial expenditure (AE) and
antibiotic cost per patient day (ACPD) increased by 33 and 22%
respectively. Increased consumption of aztreonam (78%), CEF (6%),
